Cover Image
市場調查報告書

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363571
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素2 (組蛋白去乙醯酶2) :開發中產品分析 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 116 Pages
簡介

本報告提供組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的概要

治療藥的開發

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各開發階段

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中的產品 - 各適應症

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):企業開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):大學/機關開發中的產品

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2)的治療藥的開發企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Chipscreen Biosciences Ltd
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • Italfarmaco S.p.A.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Rodin Therapeutics
  • Sigma-Tau S.p.A.
  • TetraLogic Pharmaceuticals
  • Yungjin Pharm. Co., Ltd.

藥物簡介

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):暫停中的計劃

組蛋白去乙醯酵素2 (組蛋白去乙醯酶2):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1020TDB

Summary:

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Lung Cancer, Mantle Cell Lymphoma, Neurodegenerative Diseases, Neurology, Non-Hodgkin Lymphoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Thalassemia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Asthma, Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Gallbladder Cancer, Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer.

The latest report Histone Deacetylase 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Overview
    • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Celgene Corp
    • Chipscreen Biosciences Ltd
    • Curis Inc
    • HitGen LTD
    • Italfarmaco SpA
    • Medivir AB
    • MEI Pharma Inc
    • Merck & Co Inc
    • Sigma-Tau SpA
    • Yungjin Pharm Co Ltd
    • Zhejiang Hisun Pharmaceutical Co Ltd
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles
    • 4SC-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-1035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-1071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-3158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUDC-907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • largazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1497 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCY-1992 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resminostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tucidinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YPL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Discontinued Products
  • Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
      • Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference
      • Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
      • Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
      • May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
      • May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
      • Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
      • Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action
      • Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma
      • Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup
      • Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities
      • Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities
      • Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL
      • Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
      • Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by 4SC AG, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by Chipscreen Biosciences Ltd, H2 2017
  • Pipeline by Curis Inc, H2 2017
  • Pipeline by HitGen LTD, H2 2017
  • Pipeline by Italfarmaco SpA, H2 2017
  • Pipeline by Medivir AB, H2 2017
  • Pipeline by MEI Pharma Inc, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Sigma-Tau SpA, H2 2017
  • Pipeline by Yungjin Pharm Co Ltd, H2 2017
  • Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top